Assertio Therapeutics Inc ASRT

$23.50 +0.02 (0.09%)

Valuation

Market cap
151,862,000
Revenue TTM
$118,710,000
Net income TTM
$-30,380,000
PE ratio
0.00
Forward PE
783.33
Profit margin
-25.59%
Debt to equity
0.52

Trading

Volume
274,300
Avg volume
374,140
Day's range
$23.48 – $23.50
Shares out
6,462,000
Stochastic %K
100%
Beta
0.51
Analysts
Hold
Price target
$24.43

Price

Company profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzod...

Show more

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
224 419 7106
Website
https://www.assertiotx.com
Address
100 South Saunders Road, Suite 300, Lake Forest, United States

Latest news

Stocktwits

11thestate Sep 30, 1:59 PM
You can still file a late claim in the $15.95M Spectrum Pharmaceuticals ($SPPI / $ASRT) settlement. The settlement claims that shareholders were misled about the effectiveness and FDA approval prospects of the company's lead drug candidates, Poziotinib and Rolontis. After multiple failed trials and FDA issues, $SPPI fell nearly 88%. Investors who held shares between 2018 and 2021 may still be eligible to file a late claim, subject to approval: https://11th.com/cases/spectrum-investor-settlement
0 replies
11thestate Sep 25, 1:38 PM
Shareholders who bought $SPPI / $ASRT in 2022 have until October 12, 2026 to file a claim in the $7M settlement. The settlement claims that Spectrum Pharmaceuticals misled investors about poziotinib’s dosing, FDA interactions, and the status of its PINNACLE study. Eligible investors can still submit a claim before the deadline: https://11th.com/cases/sppi-investor-settlement
0 replies
Invest2live Sep 15, 2:08 AM
$ASRT 139% already; congrats 🔆🌺🥦 Checkout $AKBA and $LUMN as well as $RXRX
2 replies
11thestate Sep 14, 2:04 PM
Imagine buying $SPPI / $ASRT at its peak, only to watch it crash more than 60% and then finding out there’s a way to get some money back. To all $SPPI investors out there, we’ve got some important news: a $7 million investor settlement is now open for claims from shareholders who purchased shares in 2022 The deadline is in two months, you can check if you’re eligible and claim your share: https://11th.com/cases/sppi-investor-settlement
0 replies
11thestate Sep 1, 12:37 PM
$SPPI stock dropped more than 37% after FDA briefing materials exposed concerns about poziotinib’s dosing and confirmatory study, ending up in a $7 million investor settlement. If you are a $SPPI /$ASRT investor, don’t miss this update. Claims are currently being accepted, and you may still be able to recover losses : https://11th.com/cases/sppi-investor-settlement Who can apply? If you bought or held $SPPI in 2022, you’re likely eligible even if you already sold your shares.
0 replies
11thestate Aug 18, 1:17 PM
Imagine buying $SPPI / $ASRT at its peak, only to watch it crash more than 85%, and then finding out you may still have a chance to recover some of your losses. To all $SPPI / $ASRT investors: there's a $15.95 million investor settlement, and late claims are currently being considered. If you purchased shares between 2018 and 2021, you may still be eligible to participate. You can check your eligibility and submit a late claim here: https://11th.com/cases/spectrum-investor-settlement
0 replies
11thestate Aug 14, 12:45 PM
FAQ: Everything you need to know about the $7M $SPPI $ASRT Settlement Payout Q: What happened? A: Spectrum Pharmaceuticals was accused of misleading investors about poziotinib’s dosing, its interactions with the FDA, and the status of the PINNACLE confirmatory study. After FDA briefing materials revealed concerns about the drug’s safety, efficacy, and dosing, $SPPI fell sharply, including a drop of more than 37% on September 20, 2022. Q: Am I actually eligible? A: If you bought $SPPI shares in 2022, you’re likely eligible. You don’t need to hold the stock still to claim; past losses count Q: When is the deadline to submit a claim? A: The current claim deadline is October 12, 2026. Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. But the exact timing depends on the court and settlement administration. Check if you're eligible and file a claim: https://11th.com/cases/sppi-investor-settlement
0 replies
11thestate Aug 3, 1:05 PM
The $15.95M Spectrum Pharmaceuticals investor settlement is now reviewing late claims. Investors who purchased $SPPI / $ASRT shares between 2018 and 2021 may still be eligible to participate, late claims are currently being accepted: https://11th.com/cases/spectrum-investor-settlement
0 replies